Comparative Pharmacology
Head-to-head clinical analysis: SULFANILAMIDE versus TRIMETHOPRIM SULFAMETHOXAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFANILAMIDE versus TRIMETHOPRIM SULFAMETHOXAZOLE.
SULFANILAMIDE vs Trimethoprim-Sulfamethoxazole
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydropteroic acid, thereby inhibiting bacterial folic acid synthesis.
Sulfamethoxazole inhibits dihydropteroate synthase, blocking para-aminobenzoic acid incorporation into dihydrofolate; trimethoprim inhibits dihydrofolate reductase, preventing tetrahydrofolate formation. Sequential blockade of folate synthesis.
2-4 g orally initially, then 2-4 g every 4-6 hours, not to exceed 12 g/day; intravenous: 4-8 g/day in divided doses every 6-8 hours.
Oral: 160 mg TMP/800 mg SMX every 12 hours; IV: 8-10 mg/kg/day (based on TMP) in 2-4 divided doses
None Documented
None Documented
Clinical Note
moderateSulfanilamide + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sulfanilamide."
Clinical Note
moderateSulfanilamide + Atorvastatin
"The risk or severity of adverse effects can be increased when Sulfanilamide is combined with Atorvastatin."
Clinical Note
moderateSulfanilamide + Mecamylamine
"The risk or severity of adverse effects can be increased when Sulfanilamide is combined with Mecamylamine."
Clinical Note
moderateTerminal elimination half-life: 7-12 hours; prolonged in renal impairment (up to 24-48 hours).
Trimethoprim: 8-10 hours (normal renal function); prolonged to 24-30 hours in severe renal impairment (CrCl <10 mL/min). Sulfamethoxazole: 9-11 hours; prolonged in renal failure. The combination retains a half-life of ~10-12 hours in healthy adults, requiring dose adjustment in renal impairment.
Primarily renal via glomerular filtration and tubular secretion; ~50-70% excreted unchanged in urine; biliary/fecal excretion minimal (<5%).
Trimethoprim: 50-60% excreted unchanged in urine via glomerular filtration and tubular secretion; 10-20% as metabolites. Sulfamethoxazole: 20-30% excreted unchanged in urine; 50-70% as N4-acetylated metabolite. Both undergo minimal biliary/fecal elimination (<5% total).
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic
Sulfanilamide + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sulfanilamide."